Highest-materiality recent filing
Bone Biologics files prospectus supplement for ATM offering of up to $1.064M in common stock
Filing covers up to $1,064,000 shares of common stock sold at market through H.C. Wainwright as sales agent.
Bone Biologics CEO updates on NB1 trial enrollment, shelf life extension, and $5M offering
Clinical trial enrollment slower than anticipated; expects to complete enrollment by year-end 2025.
Bone Biologics closes $5M public offering, net proceeds ~$4.3M
Gross proceeds $5M from 1.25M shares (or pre-funded) plus Series D/E warrants; net ~$4.3M after fees.
Bone Biologics regains Nasdaq minimum bid price compliance
Received Nasdaq notice on June 25, 2025 confirming compliance with Listing Rule 5550(a)(2).
Bone Biologics shareholders approve 30M share increase and 1-for-2.5 to 1-for-10 reverse split
Stockholders elected directors Stroever, Angle, Gagnon, and Meikle; all received >90% of votes cast (excluding broker non-votes).
Bone Biologics receives Nasdaq delisting notice for bid price below $1; plans reverse stock split
Received Nasdaq deficiency letter on April 7, 2025 for failing minimum bid price of $1 per share for 30 consecutive business days.
First two patients treated in pilot study of NB1 bone graft device for spine fusion
Two patients treated in Australia in multicenter pilot study evaluating NB1 (NELL-1+DBM) for TLIF in degenerative disc disease.
Bone Biologics closes $2.0M public offering of shares and warrants; net proceeds ~$1.5M
Priced 119,000 shares and 662,251 pre-funded warrants, each with warrants to buy one share at $2.43.
Bone Biologics reports NB1 clinical trial progress: 3 sites engaged in Australia
NB1 pilot trial: 30 adults, randomized, evaluating safety & effectiveness in TLIF for DDD.
Bone Biologics settles breach-of-contract lawsuit for $750,000 cash payment
Company will pay plaintiffs $750,000 cash within 20 business days of the January 9, 2024 effective date.
Bone Biologics regains Nasdaq minimum bid price compliance; stock continues listing
Received Nasdaq notice confirming compliance with minimum bid price rule (Rule 5550(a)(2)).
Stockholders approve reverse stock split; Nasdaq grants continued listing until Jan 12, 2024
Stockholders voted 1,402,685 for, 162,168 against, 16,129 abstain to authorize reverse stock split at ratio 1:5 to 1:20.
Bone Biologics receives Nasdaq delisting notice for bid price non-compliance
Received Nasdaq staff determination to delist due to failure to maintain $1.00 minimum bid price.
On October 16, 2024, the Board of Directors (the “Board”) of Bone Biologics Corporation (the “Company”) appointed Phillip Meikle to the Company’s Board.
On October 1, 2024, Don Hankey informed Bone Biologics Corporation (the “Company”) of his resignation as a director of the Company effective immediately.
On January 8, 2024, the Board of Directors of Bone Biologics Corporation (the “Company”) appointed Robert E. Gagnon to the Company’s Board of Directors.
As previously disclosed, Erick Lucera resigned from the Board of Directors on December 27, 2023, effective as of the date Mr. Gagnon was appointed.
On December 27, 2023 Erick Lucera resigned as a director of the Company, effective upon the appointment of a new director.
Max materiality 0.85 · Median 0.53 · Most common event other_material